Private-Sector Research Ethics: Marketing
or Good Conflicts Management? The 2005 John J. Conley Lecture on Medical Ethics Article DOI:
Cite this article as: Dresser, R. Theor Med Bioeth (2006) 27: 115. doi:10.1007/s11017-005-5289-5 Abstract
Pharmaceutical companies are major sponsors of biomedical research. Most scholars and policymakers focus their attention on government and academic oversight activities, however. In this article, I consider the role of pharmaceutical companies’ internal ethics statements in guiding decisions about corporate research and development (R&D). I review materials from drug company websites and contributions from the business and medical ethics literature that address ethical responsibilities of businesses in general and pharmaceutical companies in particular. I discuss positive and negative uses of pharmaceutical companies’ ethics materials and describe shortcomings in the companies’ existing ethics programs. To guide employees and reassure outsiders, companies must add rigor, independence, and transparency to their R&D ethics programs.
Keywords business ethics conflicts of interest corporate responsibility pharmaceutical companies research ethics scientific integrity References
Amgen. Available at
Angell, M. 2004The Truth about the Drug Companies: How They Deceive Us, and What to Do about It Random House New York Google Scholar
AstraZeneca. Available at
Avorn, J. 2004Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs Knopf New York Google Scholar
Berenson, A. “Despite Vow, Drug Makers Still Withhold Data.”
New York Times. May 31, 2005, A1. Brock, D. 2001 Some Questions about the Moral Responsibilities of Drug Companies in Developing Companies Developing World Bioethics 1 33 37 CrossRef Google Scholar Couzin, J. 2005 Facing Criticism, Industry Offers to Share Data Science 307 89 CrossRef Google Scholar Croghan, T., Pittman, P. 2004 The Medicine Cabinet: What’s in It, Why, and Can We Change the Contents? A Framework for Aligning Business Objectives with Medical Need Health Affairs 23 23 33 CrossRef Google Scholar Angelis, C., Drazen, J., Frizelle, F., et al. 2004 Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors New England Journal of Medicine 351 1250 1251 CrossRef Google Scholar Maistre, J. 1992) “Letter to X” Kaplan, J. eds. Bartlett’s Familiar Quotations16 Little, Brown Boston Google Scholar Dhanda, R. 2002Guiding Icarus: Merging Bioethics with Corporate Interests John Wiley & Sons New York Google Scholar Dresser, R. 2001When Science Offers Salvation: Patient Advocacy and Research Ethics Oxford University Press New York Google Scholar Dresser, R. 2005 A New Era in Drug Regulation? Hastings Center Report 35 10 11 CrossRef Google Scholar DuVal, G. 2004 Institutional Conflicts of Interest: Protecting Human Subjects, Scientific Integrity, and Institutional Accountability Journal of Law, Medicine & Ethics 32 613 625 Google Scholar Eaton, M. 2004Ethics and the Business of Bioscience Stanford Business Books Palo Alto Google Scholar
Friedman, M. “The Social Responsibility of Business Is to Increase Its Profits.”
New York Times Magazine, September 13, 1970, 32–33, 122–126.
GlaxoSmithKline. Available at
Goodpasture, K. and J. Mathews. “Can a Corporation Have a Conscience?” In
Harvard Business Review on Corporate Responsibility. 131–155. Boston: Harvard Business School Press, 2003.
Hahn, H. “The Flaws in a Heart Device.”
New York Times, May 31, 2005, A18.
Johnson & Johnson. Available at
Levinsky, N. 2002 Nonfinancial Conflicts of Interest in Research New England Journal of Medicine 347 759 761 CrossRef Google Scholar Mello, M., Clarridge, B., Studdert, D. 2005 Academic Medical Centers’ Standards for Clinical-Trial Agreements with Industry New England Journal of Medicine 352 2202 2210 CrossRef Google Scholar
Merck. Available at
NDCHealth, “Excerpts from 2005 Pharma Insight.” Available at
Olsen, N. 2005 Tailoring Arthritis Therapy in the Wake of the NSAID Crisis New England Journal of Medicine 352 2578 2580 CrossRef Google Scholar Paine, L.S. 2003Value Shift: Why Companies Must Merge Social and Financial Imperatives to Achieve Superior Performance McGraw-Hill New York Google Scholar
Pfizer, Inc. Available at
PhRMA. Available at
Porter, M. and Kramer, M. “The Competitive Advantage of Corporate Philanthropy.” In
Harvard Business Review on Corporate Responsibility. 27–64. Boston: Harvard Business School Press, 2003. Psaty, B., Furberg, C., Ray, W., Weiss, N. 2004 Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis Journal of the American Medical Association 292 2629 Google Scholar
Relman, A. and M. Angell, “America’s Other Drug Problem.”
The New Republic, December 16, 2002, 27–41.
Roche Group. Available at
Spencer, E., Mills, A., Rorty, M., Werhane, P. 2000Organizational Ethics in Health Care Oxford University Press New York Google Scholar Steinbrook, R. 2005 Gag Clauses in Clinical-Trial Agreements New England Journal of Medicine 352 2160 2162 CrossRef Google Scholar Strom, B. 2004 Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: A Counterpoint Journal of the American Medical Association 292 2643 2646 CrossRef Google Scholar
Thompson, D. “The Privatization of Business Ethics.” In
Restoring Responsibility: Ethics in Government, Business, and Healthcare. Cambridge: Cambridge University Press, 2005.